Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1351
CALL
Constellation Energy
CEG
$91.2B
| $16.6M | ﹤0.01% |
47,000
-12,200
| -21% | -$4.43M |
2024 Q1
7 quarters
|
|
1352
CALL
Fluor
FLR
$6.67B
| $16.5M | ﹤0.01% |
416,600
-310,100
| -43% | -$13.7M |
2025 Q3
1 quarter
|
|
1353
Old Republic International
ORI
$9.19B
| $16.5M | ﹤0.01% |
361,471
-166,605
| -32% | -$7.23M |
2013 Q2
50 quarters
|
|
1354
BioNTech
BNTX
$24.3B
| $16.5M | ﹤0.01% |
173,089
+156,832
| +965% | +$15.8M |
2022 Q1
15 quarters
|
|
1355
CALL
Suncor Energy
SU
$81.4B
| $16.4M | ﹤0.01% |
370,000
| – | – |
2024 Q4
4 quarters
|
|
|
1356
PUT
Suncor Energy
SU
$81.4B
| $16.4M | ﹤0.01% |
370,000
| – | – |
2024 Q4
4 quarters
|
|
1357
Protagonist Therapeutics
PTGX
$9.06B
| $16.4M | ﹤0.01% |
187,642
+16,236
| +9% | +$1.33M |
2018 Q4
28 quarters
|
|
1358
CALL
Cipher Digital
CIFR
$6.52B
| $16.4M | ﹤0.01% |
+1,108,100
| New | +$19.6M |
2025 Q4
0 quarters
|
|
|
VG
1359
PUT
Venture Global Inc
VG
$32.8B
| $16.3M | ﹤0.01% |
2,390,000
+699,300
| +41% | +$5.83M |
2025 Q2
2 quarters
|
|
1360
Bio-Techne
TECH
$11.4B
| $16.3M | ﹤0.01% |
277,010
-7,837
| -3% | -$476K |
2013 Q2
50 quarters
|
|
1361
Ingredion
INGR
$6.01B
| $16.3M | ﹤0.01% |
147,619
+25,414
| +21% | +$2.87M |
2013 Q2
50 quarters
|
|
1362
Watts Water Technologies
WTS
$12.1B
| $16.3M | ﹤0.01% |
58,928
-4,373
| -7% | -$1.21M |
2013 Q2
50 quarters
|
|
1363
Victory Capital Holdings
VCTR
$6.96B
| $16.3M | ﹤0.01% |
257,696
-57,445
| -18% | -$3.66M |
2022 Q1
15 quarters
|
|
1364
Jazz Pharmaceuticals
JAZZ
$15.3B
| $16.2M | ﹤0.01% |
95,312
+29,733
| +45% | +$4.56M |
2013 Q4
48 quarters
|
|
1365
CALL
Galicia Financial Group
GGAL
$5.76B
| $16.2M | ﹤0.01% |
+300,000
| New | +$14M |
2025 Q4
0 quarters
|
|
|
FOLD
1366
DELISTED
Amicus Therapeutics
FOLD
| $16.2M | ﹤0.01% |
1,134,639
+165,117
| +17% | +$1.62M |
2016 Q3
37 quarters
|
|
1367
ACI Worldwide
ACIW
$5.06B
| $16.2M | ﹤0.01% |
337,917
+138,354
| +69% | +$6.71M |
2013 Q2
50 quarters
|
|
1368
APA Corp
APA
$15.3B
| $16.1M | ﹤0.01% |
660,180
-176,753
| -21% | -$4.28M |
2022 Q1
15 quarters
|
|
1369
Eos Energy Enterprises
EOSE
$1.17B
| $16.1M | ﹤0.01% |
1,408,419
+1,037,154
| +279% | +$14.9M |
2022 Q1
15 quarters
|
|
1370
Flowserve
FLS
$9.45B
| $16.1M | ﹤0.01% |
232,464
-127,727
| -35% | -$8.21M |
2013 Q2
50 quarters
|
|
1371
Eastern Bankshares
EBC
$4.9B
| $16.1M | ﹤0.01% |
874,433
+170,547
| +24% | +$3.12M |
2022 Q1
15 quarters
|
|
1372
Federal Signal
FSS
$7.1B
| $16.1M | ﹤0.01% |
148,388
+29,372
| +25% | +$3.36M |
2016 Q1
39 quarters
|
|
1373
Pinnacle Financial Partners Inc
PNFP
$14.5B
| $16.1M | ﹤0.01% |
168,345
+47,683
| +40% | +$4.38M |
2016 Q1
39 quarters
|
|
1374
ABM Industries
ABM
$2.87B
| $16M | ﹤0.01% |
379,147
+276,232
| +268% | +$12.1M |
2013 Q2
50 quarters
|
|
1375
ATI
ATI
$26.2B
| $16M | ﹤0.01% |
139,544
-180,147
| -56% | -$17.6M |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.